Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed and Refractory Follicular Lymphoma: Analysis of Safety, Efficacy, and Minimal Residual Disease

Authors :: Christopher Melani
Rahul Lakhotia
Stefania Pittaluga
James D. Phelan
Jillian Simard
Jagan R. Muppidi
Craig J. Thomas
Michele Ceribelli
Frances Anne Tosto
Rafic J. Farah
Seung Tae Lee
Amynah Pradhan
Anna Marie Juanitez
Seth M. Steinberg
Elaine S. Jaffe
Mark Roschewski
Louis M. Staudt
Wyndham H. Wilson
Source :: Blood. 140:2289-2291
Publication Year :: 2022
Publisher :: American Society of Hematology, 2022.

Tools